Similar not same. The sites work TOGETHER. Like picking up a shovel without three fingers, you can do it but it's a lot more difficult. This is probably one reason why RVX208 has been shown to be much less potent than JQ1 on a number of pathways which likely contributes to its good safety profile. 

"The transcriptional effect of (+)-JQ1 is 10x higher than that of RVX-208"

Furthermore, based on the abundance of available data on apabetalone, there is simply no way to see the level of impact without targeting the mitochondria. There is no removal of inflammation, no improvement of kidney function, no reduction in atherosclerosis without an improvement in the mitochondria.